Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. (Nasdaq:KERX). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.microstockprofit.com/ads/KERX

Keryx Biopharmaceuticals Inc. (KERX) engages in the acquisition, development and commercialization of drug therapies for the treatment of renal disease and cancer. The Company's novel, oral anti-cancer agent called KRX-0401 (perifosine) is developed to inhibit cell growth and cell transformation. KRX-0401 has cleared Phase I clinic trials for safety and efficacy. KRX-0401 is currently in Phase II clinical trials to determine efficacy for multiple tumor types, and Phase III for the efficacy to treat multiple myeloma. The Company seeks strategic relationships to develop drug candidates, including evaluating compounds for acquisition or licensing.  

Message Board Search for KERX: http://www.boardcentral.com/boards/KERX

In the report, the analyst notes:

"KRX-0401 (perifosine) is the Company's lead oral anti-cancer agent developed to modulate important signal transduction pathways, including the JNK and MAPK pathways. JNK and MAPK are identified as the pathways associated with the growth, differentiation, death and survival of human cells. KRX-0401 modulates the Akt pathway, which is believed to be the pathway for the development of most cancers. The Company has evidence that these pathways are activated in tumors that have historically resisted traditional anticancer therapies. The Company's challenge is to inhibit this pathway without excessive toxicity to the patient. 

"Recent media coverage of the stock and its leading drug candidate has recently been accelerating as perifosine nears completion of the FDA process and further demonstrates efficacy, safety and potential to treat other conditions. 

"The market potential for perifosine and like drugs is estimated to reach more than $10 billion, worldwide, with potential revenue from commercialization of the drug and market capitalization implications of the Company raised substantially if perifosine clears the FDA."